Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Galectin Therapeutics (NASDAQ:GALT) Stock Rockets: How Far Can It Go?

Those who are monitoring the action in the premarket trading period may have noticed that the Galectin Therapeutics Inc (NASDAQ:GALT) has emerged as an early winner and soared by 50% at the time of writing.

This morning the company announced positive top line data with regards to the combination therapy of KEYTRUDA and Belapectin, which is meant for the treatment of patients suffering from progressive diseases. The data revealed that the combination therapy clocked cancer control rate of as much as 56% in case of melanoma and 40% in case of head and neck cancer. Hence, it is no surprise that investors have piled on to the stock this morning following the update from Galectin.

The announcement was made by the company jointly with the Earle A. Chiles Research Institute, which is a branch of the Providence Cancer Institute. The study was done under the guidance of well known melanoma and cancer specialist Dr. Brendan D. Curti. In this regard, it is also necessary to note that the patients suffering from melanoma also recorded some serious prognosis. Out of the nine patients, four had choroidal primary tumors and six were suffering from liver metastasis.

GALT stock is up by 45.30% to $4.01 in the pre-market session on high volume.

Published by Madison Hall

After graduating from the University of Buffalo, Madison gained a real interest in the markets. She tends to be a swing trader and enjoys Pilates and yoga in her downtime.

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
*By submitting your information you agree to the terms of our Privacy Policy. You will receive the DRP Journal newsletter, and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.